-+ 0.00%
-+ 0.00%
-+ 0.00%
Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Share
Listen to the news

– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –

– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10 mmol/L) and at high risk of developing acute pancreatitis –

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending